Study: Ritalin treats apathy in patients with Alzheimer's disease

February 5, 2013 by Cynthia Billhartz Gregorian

Leslye Nathe did not realize the profound effect that Ritalin was having on her mother's Alzheimer's disease until a doctor stopped the prescription.

Her mother, Susan Brown, 74, a resident at Provision Living in Webster Groves, Mo., began sleeping nearly all the time. And during rare moments, when she was awake, she was tearing the sheets off of her bed and scratching wounds into her arms.

"She was like a child having a tantrum and she kept telling people to leave. She was very paranoid," Nathe said. "She would beg me, 'Please, please get me some medication. There's something wrong. I can't deal with it anymore.'"

Brown had been taking Ritalin for many years even before she was diagnosed with Alzheimer's, to treat and depression.

When her physician, Dr. George Grossberg, director of at St. Louis University, heard about her alternating bouts of and meltdowns, he put Brown back on the Ritalin.

Her reaction to being taken off the drug was more extreme than usual, but it supported the long-held notion that Ritalin is key to controlling some Alzheimer's symptoms.

Grossberg and a team of researchers at the university, recently received a $183,540 grant from Noven Pharmaceuticals Inc. to study Ritalin as a therapy for and fall risk in Alzheimer's patients. Both are common symptoms of Alzheimer's disease, affecting about 70 percent patients who have it.

Noven is a joint-venture partner of Pharmaceuticals, which manufactures Ritalin. Novartis paid Grossberg $28,000 in 2010 to speak about its products to other physicians.

Grossberg said family members frequently notice that loved ones are indifferent, socially disengaged and have lost all enthusiasm.

"It's serious couch-potatoism, and it drive relatives crazy," Grossberg said. "There's a lot of evidence that Ritalin has mood-elevating effects and also makes them more aware of their environment and obstacles. They also make better decisions."

Scientists are not sure what causes apathy in patients with Alzheimer's disease but early data indicate that it might be related to a decrease in the transmission of dopamine, a feel-good chemical in the brain. Ritalin, which is commonly used to treat attention deficit disorder, increases the transmission of dopamine in the brain.

A previous international clinical trial, funded by the National Institute on Aging, showed marked improvements on clinical testing for apathy among Alzheimer's patients who were given Ritalin compared to those who were not.

"Once you have depression, or apathy in this case, it makes it harder to focus on the environment," Grossberg said. "So by improving patients' energy levels, we think it will contribute to them being less likely to fall."

Falling and balance do not involve the hippocampus, which is most responsible for memory and most profoundly affected by the disease.

"But in the balance section of brain, there may be cells dying or chemical alterations that increase the risk for falls. It could be a combination of different things," Grossberg said.

"We do know that there are extremely high rates of apathy and that the risk of falls is much higher in Alzheimer's patients than in age-matched non-Alzheimer's patients," he said.

"It's very safe," Grossberg said. "We're using ultra-low doses in patch form. A lot of older people with Alzheimer's have trouble swallowing. Plus, with the patch you can have a gradual introduction to the blood stream and keep it level without peaks and valleys. So it's better tolerated."

When Nathe told Grossberg about her mother's behavior after being taken off the , "he said, 'you know your mom's history. Let's go with what you're saying,'" Nathe said. "Within two days she was back to her normal self. And Grossberg adjusted other medications for her mood disorders, which helped.

"My mom is on 5 mg in the morning and 5 mg after lunch. That's not very much," Nathe said. "But it worked and it works now. I want her up and participating in as many things as she can. And that's what she does now."

Grossberg and his team are in the process of recruiting 40 St. Louis-area Alzheimer's at three nursing homes to participate in the four-week study. They hope to have data within a year.

"This is a high-risk population for falls, so they have to be watched round the clock to see if they tolerate the treatments and don't fall," Grossberg said. "Plus we need continuous observation to see what the results are."

Explore further: Falls may be early sign of Alzheimer's

Related Stories

Falls may be early sign of Alzheimer's

July 18, 2011
Falls and balance problems may be early indicators of Alzheimer’s disease, researchers at Washington University School of Medicine in St. Louis report July 17, 2011, at the Alzheimer’s Association International ...

Recommended for you

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.